Pleomorphic xanthoastrocytoma

Lore & Background

Pleomorphic xanthoastrocytoma is diagnosed through a combination of clinical exam, CT or MRI scans (sometimes with contrast dye), EEG for seizure patients, and biopsy. Surgery is often the treatment of choice; total resection is often possible. If the tumor is completely removed, further treatment may not be required, though repeated MRIs are needed to monitor for regrowth. For tumors that recur or cannot be completely removed, radiation therapy may be recommended.

Reader's Guide

Pleomorphic xanthoastrocytoma is significant as a brain tumor with a favorable prognosis when completely resected, offering a 90% long-term survival rate. Its occurrence primarily in children and teenagers makes it a focus of pediatric neuro-oncology. The tumor's superficial location often allows for surgical removal, reducing the need for additional therapies. However, incomplete resection lowers survival to above 50%, and high-grade anaplastic variants carry higher fatality. The Pediatric Brain Tumor Consortium, comprising nine U.S. institutions, offers experimental therapies for progressive or recurrent cases not responsive to standard treatments. Understanding PXA helps guide treatment decisions balancing surgical resection, radiation, and monitoring, while managing risks such as seizures and brain damage from surgery or radiation-induced swelling.

Did You Know?

• In about 20% of cases, the tumor exists in more than one lobe of the brain.
• After complete surgical resection, the long-term survival rate is 90%; after incomplete resection, it is higher than 50%.
• The Pediatric Brain Tumor Consortium (PBTC) includes more than a dozen institutions in the United States and conducts research on experimental therapies for a range of pediatric brain tumors, not just PXA.